more

Anixa Biosciences (ANIX)

(Delayed Data from NSDQ)

$3.44 USD

-0.18 (-4.97%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $3.39 -0.05 (-1.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Zacks News

Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing

by Zacks Equity Research Published on May 18,2023

Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.

biotechs

Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag

by Zacks Equity Research Published on May 17,2023

Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.

biotechs

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research Published on May 16,2023

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

biotechs

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

by Zacks Equity Research Published on May 12,2023

Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.

biotechs

Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

by Zacks Equity Research Published on May 10,2023

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

biotechs

Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates

by Zacks Equity Research Published on May 09,2023

Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.

biotechs

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on April 25,2023

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

by Zacks Equity Research Published on April 18,2023

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

biotechs

Here's What Could Help ANIXA BIOSCIENCES INC (ANIX) Maintain Its Recent Price Strength

by Zacks Equity Research Published on April 14,2023

ANIXA BIOSCIENCES INC (ANIX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

ANIXNegative Net Change

What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"

by Zacks Equity Research Published on October 28,2022

ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

ANIXNegative Net Change

Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on May 02,2022

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

by Zacks Equity Research Published on December 08,2021

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study

by Zacks Equity Research Published on August 31,2021

The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.

Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates

by Zacks Equity Research Published on April 21,2021

The biotech sector was in focus last week with regulatory updates from Bristol Myers (BMY), among others.

biotechs